|
Synonyms: Defitelio®
defibrotide is an approved drug (EMA (2013), FDA (2016))
Compound class:
Natural product
Comment: Defibrotide is a deoxyribonucleic acid derivative (single-stranded) purified from bovine lung. It has anticoagulant activity. Defibrotide is administered as defibrotide sodium. As this is a natural extract, its composition is not fully resolved, so no chemical structure is provided.
|
| References |
|
1. Hopps SA, Borders EB, Hagemann TM. (2016)
Prophylaxis and treatment recommendations for sinusoidal obstruction syndrome in adult and pediatric patients undergoing hematopoietic stem cell transplant: a review of the literature. J Oncol Pharm Pract, 22 (3): 496-510. [PMID:26126501] |
|
2. Keating GM. (2014)
Defibrotide: a review of its use in severe hepatic veno-occlusive disease following haematopoietic stem cell transplantation. Clin Drug Investig, 34 (12): 895-904. [PMID:25351934] |
|
3. Niada R, Mantovani M, Prino G, Pescador R, Porta R, Berti F, Folco GC, Omini C, Viganò T. (1982)
PGI2-generation and antithrombotic activity of orally administered defibrotide. Pharmacol Res Commun, 14 (10): 949-57. [PMID:6818564] |
|
4. Pescador R, Mantovani M, Prino G, Madonna M. (1983)
Pharmacokinetics of Defibrotide and of its profibrinolytic activity in the rabbit. Thromb Res, 30 (1): 1-11. [PMID:6687960] |
|
5. Pescador R, Porta R, Ferro L. (1996)
An integrated view of the activities of defibrotide. Semin Thromb Hemost, 22 Suppl 1: 71-5. [PMID:8807733] |
|
6. Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, Arai S, Grupp SA, Guinan EC, Martin PL et al.. (2016)
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood, 127 (13): 1656-65. [PMID:26825712] |
